Lundbeck/Biotie Aim To Open Up Alcoholism Market By Trying To Reduce, Not Stop, Drinking
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
H. Lundbeck AS is planning to file for approval in Europe in the second half of 2011 for nalmefene – a drug touted as a novel and potentially revolutionary way of treating alcoholism – but currently is not planning to file in the U.S., presumably due to intellectual property issues.
You may also be interested in...
Lundbeck Leans On Licensing To Overcome Lexapro/Cipralex Expiry
As lead drug Lexapro/Cipralex faces genericization, Lundbeck is counting on revenues from ongoing licensing deals to fill the $1 billion hole.
Lundbeck Leans On Licensing To Overcome Lexapro/Cipralex Expiry
As lead drug Lexapro/Cipralex faces genericization, Lundbeck is counting on revenues from ongoing licensing deals to fill the $1 billion hole.
Alcoholism Drugs Wanted: Uncle Sam Offers Industry A Hand in R&D
As awareness of the biology of addiction slowly begins to take hold among the general population, medications could wind up being the next best thing to a Higher Power in helping to keep alcoholics sober